RYI-018

Bird Rock Bio, Inc. · Phase 1 active Biologic

At a glance

Generic name	RYI-018
Sponsor	Bird Rock Bio, Inc.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RYI-018 CI brief — competitive landscape report
RYI-018 updates RSS · CI watch RSS
Bird Rock Bio, Inc. portfolio CI